SCHEMBL30752591

SCHEMBL30752591

CN(c1nc(Cl)nc2c(F)c(Br)c(C(F)(F)F)cc12)C1CC(O[Si](C)(C)C(C)(C)C)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30752616 0.89 — —
SCHEMBL30752568 0.88 — —
SCHEMBL30752565 0.88 — —
SCHEMBL30752566 0.88 — —
SCHEMBL30752575 0.84 — —
SCHEMBL30752590 0.81 — —
SCHEMBL30752563 0.79 — —
SCHEMBL30752633 0.77 GBA1 (0.33) —
SCHEMBL32672703 0.75 HTT (0.37) —
SCHEMBL30752634 0.75 HTT (0.37) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042764-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS THERAS INC (US) 2026-02-12 — — US disclosed
EP-4565579-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS Theras, Inc. (US) 2025-06-11 — — EP disclosed
Send feedback